- Global Pharma News & Resources

TrakCel and Mustang Bio partner on CAR T supply chain management and orchestration platform

TrakCel, the software developer for cell and gene therapy supply chain tracking and orchestration systems, and Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a Fortress Biotech (NASDAQ: FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, today announce that they have partnered to build a custom-configured cellular supply chain tracking and orchestration platform. The platform will be used in the clinical development and commercialization of Mustang’s CAR T therapies. Financial details of the partnership have not been disclosed. 


The software platform will enable Mustang’s clinical and logistics teams to have complete visibility across all protocols down to the individual patient level, with a comprehensive electronic record trail and the ability to capture data across all activities, from patient T cell collection to drug infusion. 


The platform will be integrated into Mustang’s proprietary CAR T cell therapy manufacturing facility in Worcester, Mass., U.S., and is expected to be operational by the first quarter of 2019. TrakCel will also integrate the platform into the operations of Mustang’s multiple supply chain partners, including collection centers, couriers and other third parties. 


“An overview across the entire supply chain is critical to the successful development and delivery of CAR T product candidates,” said Knut Niss, Ph.D., Chief Technology Officer of Mustang. “Mustang selected TrakCel for its ability to configure and build a custom cellular orchestration platform that will specifically meet Mustang’s needs, scale with development, and integrate with our existing systems. This will enable Mustang to decrease the complexities and risks involved in developing autologous CAR T technologies, which have previously used manual and paper-based methods. This may decrease the costs of goods by improving efficiencies throughout the supply chain and ensuring the quality of our CAR T product candidates from needle-to-needle, initiating at collection and ending at infusion. Moreover, the platform will enable us to improve product safety and regulatory compliance, confirming that the correct CAR T therapy is delivered to the right patient every time.”


“TrakCel is custom configuring orchestration platforms for companies leading development across the international cell therapy sector. We have built unrivalled experience and acquired the know-how to provide the critical support needed by cell and gene therapy developers,” said Ravi Nalliah, CEO of TrakCel. “Managing supply chains become so complex for some companies that it uses valuable resources that hinder development of much-needed therapies. TrakCel will aid Mustang to use its investment in its in-house man